A Phase 1 Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel using a novel Randomized Continual Reassessment Method for Dose Escalation

CONCLUSIONS: The combination of BAY with paclitaxel was associated with considerable toxicity without a therapeutic window. However, the use of the rCRM design enabled us to determine the exposure-toxicity relation for BAY. Therefore we propose that the rCRM could improve dose determination in phase I trials that combine agents with overlapping toxicities.PMID:34518310 | DOI:10.1158/1078-0432.CCR-20-4185

Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Florence Atrafi Oliver Boix Vivek Subbiah Jennifer R Diamond Sant P Chawla Anthony W Tolcher Patricia M LoRusso Joseph Paul Eder Martin Gutierrez Kumar Sankhala Prabhu Rajagopalan Isabelle Genvresse Simon Langer Ron Hj Mathijssen Jaap Verweij Ingmar Bruns Source Type: research